Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies
NCT00239239
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
44
Enrollment
INDUSTRY
Sponsor class
Conditions
Non-Myeloid Malignancies
Anemia
Cancer
Interventions
DRUG:
Darbepoetin alfa
Sponsor
Amgen